Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis. / Bossen, Lars; Rebora, Paola; Bernuzzi, Francesca; Jepsen, Peter; Gerussi, Alessio; Andreone, Pietro; Galli, Andrea; Terziroli, Benedetta; Alvaro, Domenico; Labbadia, Giancarlo; Aloise, Chiara; Baiocchi, Leonardo; Giannini, Edoardo; Abenavoli, Ludovico; Toniutto, Pierluigi; Marra, Fabio; Marzioni, Marco; Niro, Grazia; Floreani, Annarosa; Møller, Holger J.; Valsecchi, Maria G.; Carbone, Marco; Grønbæk, Henning; Invernizzi, Pietro.
I: Liver International, Bind 40, Nr. 6, 06.2020, s. 1408-1414.Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review
}
TY - JOUR
T1 - Soluble CD163 and mannose receptor as markers of liver disease severity and prognosis in patients with primary biliary cholangitis
AU - Bossen, Lars
AU - Rebora, Paola
AU - Bernuzzi, Francesca
AU - Jepsen, Peter
AU - Gerussi, Alessio
AU - Andreone, Pietro
AU - Galli, Andrea
AU - Terziroli, Benedetta
AU - Alvaro, Domenico
AU - Labbadia, Giancarlo
AU - Aloise, Chiara
AU - Baiocchi, Leonardo
AU - Giannini, Edoardo
AU - Abenavoli, Ludovico
AU - Toniutto, Pierluigi
AU - Marra, Fabio
AU - Marzioni, Marco
AU - Niro, Grazia
AU - Floreani, Annarosa
AU - Møller, Holger J.
AU - Valsecchi, Maria G.
AU - Carbone, Marco
AU - Grønbæk, Henning
AU - Invernizzi, Pietro
PY - 2020/6
Y1 - 2020/6
N2 - Introduction: In primary biliary cholangitis (PBC), macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in patients with PBC. Methods: We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (a) death from a liver-related cause; or (b) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long-term prognosis. Results: In total, 202 PBC patients were included. Median age was 62 years (interquartile range (IQR), 53-71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48-5.35) and median sMR was 0.35 mg/L (IQR 0.28-0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two hundred and one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long-term risk of liver-related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR = 1.14, 95% CI 1.00-1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK-PBC risk score. Conclusion: The macrophage activation markers sCD163 and sMR represent a non-invasive measure of PBC disease severity that provides useful long-term prognostic information.
AB - Introduction: In primary biliary cholangitis (PBC), macrophages are involved in liver inflammation and fibrosis. The macrophage activation markers, soluble (s)CD163 and mannose receptor (sMR) are associated with liver disease severity and prognosis in other chronic liver diseases. We aimed to investigate sCD163 and sMR in patients with PBC. Methods: We investigated PBC patients from the Italian PBC Study Group cohort and measured macrophage activation markers in serum at study enrolment. Patients were followed from enrolment until they experienced an event or were censored at their last visit. Events were defined as follows: (a) death from a liver-related cause; or (b) liver transplantation (LT) for PBC. We used Cox regression to investigate the association between sCD163 and sMR and long-term prognosis. Results: In total, 202 PBC patients were included. Median age was 62 years (interquartile range (IQR), 53-71) at enrolment and 93% were women. Median sCD163 was 3.43 mg/L (IQR 2.48-5.35) and median sMR was 0.35 mg/L (IQR 0.28-0.45). There was an increase in sCD163 and sMR with increasing alkaline phosphatase. Two hundred and one patients were followed for a median of 8.6 years, and sCD163 and sMR predicted long-term risk of liver-related death or LT in univariate analyses, while sCD163 was also associated with outcome after confounder adjusting (adjusted HR = 1.14, 95% CI 1.00-1.30). Finally, we showed an increase in the prediction accuracy of poor outcome by adding sCD163 to the UK-PBC risk score. Conclusion: The macrophage activation markers sCD163 and sMR represent a non-invasive measure of PBC disease severity that provides useful long-term prognostic information.
KW - macrophage activation markers
KW - non-invasive markers
KW - primary biliary cholangitis
KW - prognostic markers
UR - http://www.scopus.com/inward/record.url?scp=85083798684&partnerID=8YFLogxK
U2 - 10.1111/liv.14466
DO - 10.1111/liv.14466
M3 - Journal article
C2 - 32279422
AN - SCOPUS:85083798684
VL - 40
SP - 1408
EP - 1414
JO - Liver International
JF - Liver International
SN - 1478-3223
IS - 6
ER -